Veracyte VCYT Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $28.71M-30.2% | $41.15M+115% | $19.14M+2,053% | -$980K-114% | $7.05M+37.8% | ||
| $5.43M+2.5% | $5.3M+0.6% | $5.27M-4.1% | $5.49M+2.4% | $5.36M-14.2% | ||
| $12.76M+17.1% | $10.9M+1.3% | $10.76M-2.1% | $10.99M+0.2% | $10.96M+13.8% | ||
| -$366K— | —— | —— | -$15K— | $0+100% | ||
| $5.57M— | —— | —— | —— | $7.05M— | ||
| $2.59M+626% | -$492K+86.6% | -$3.66M+8.7% | -$4.01M-156% | $7.12M+625% | ||
| $132K+168% | -$194K+88.7% | -$1.72M-214% | $1.51M+1,339% | -$122K— | ||
| -$319K+60.1% | -$799K-61.4% | -$495K+18.7% | -$609K-5.5% | -$577K-102% | ||
| -$350K+97.2% | -$12.58M— | $0+100% | -$925K+52.7% | -$1.95M-311% | ||
| $35.22M-33.0% | $52.58M+17.5% | $44.76M+33.2% | $33.61M+527% | $5.36M-78.1% | ||
| $2.96M-21.6% | $3.78M+35.4% | $2.79M+117% | $1.29M-29.3% | $1.82M-56.1% | ||
| $125M+150% | $50M— | $0-100% | $50M0.0% | $50M0.0% | ||
| -$127.96M-2,257% | -$5.43M— | —— | -$224K+99.6% | -$51.82M+4.3% | ||
| $2.74M-22.1% | $3.51M-39.4% | $5.79M+219% | $1.81M-38.9% | $2.97M-9.1% | ||
| $9.36M+156% | $3.66M+30.0% | $2.81M+18.2% | $2.38M-74.8% | $9.45M+189% | ||
| -$6.63M-4,349% | -$149K— | —— | -$566K+91.3% | -$6.48M— | ||
| -$58K-583% | $12K-80.0% | $60K-89.5% | $573K+674% | $74K+118% | ||
| -$99.43M-311% | $47.02M-51.1% | $96.06M+188% | $33.39M+163% | -$52.87M— | ||
| $164K— | —— | $835K-41.7% | $1.43M+1,083% | $121K-88.3% | ||
| $614K-5.7% | $651K— | —— | —— | $882K+149% | ||
| -$350K+97.2% | -$12.58M— | $0+100% | -$925K+52.7% | -$1.95M-311% | ||
| $80K— | —— | —— | $3.47M+119% | $1.59M+155% | ||
| -$6.12M— | —— | $9.13M— | —— | -$8.89M— | ||
| $870K— | —— | —— | —— | $2.3M— | ||
| -$319K+60.1% | -$799K-61.4% | -$495K+18.7% | -$609K-5.5% | -$577K-102% | ||
| $1.31M— | —— | $956K-62.2% | $2.53M-13.5% | $2.93M+103% | ||
| $732K+4.3% | $702K+1.9% | $689K-1.0% | $696K-23.0% | $904K-31.9% | ||
| -$10K+98.2% | -$568K-553% | -$87K-247% | $59K+293% | $15K+106% | ||
| $125M+150% | $50M— | $0-100% | $50M0.0% | $50M0.0% | ||
| $2.32M+56.6% | $1.48M+358% | $323K— | —— | $977K+54.1% | ||
| —— | $711.25K0.0% | $711.25K0.0% | $711.25K0.0% | $711.25K— | ||
| -$319K+60.1% | -$799K-61.4% | -$495K+18.7% | -$609K-5.5% | -$577K-102% | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| $32.25M-33.9% | $48.8M+16.3% | $41.97M+29.8% | $32.32M+812% | $3.54M-82.6% | ||
| $32.25M-33.9% | $48.8M+16.3% | $41.97M+29.8% | $32.32M+812% | $3.54M-82.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Veracyte's cash flow data come from?
- Every line is extracted from Veracyte's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.